Novartis, Valeant bids herald new deal-making era for pharma

(Reuters) - A series of agreed or proposed drug company deals may herald a new era of acquisitions not seen since last decade as pharmaceutical companies improve their best businesses and exit weaker ones. Novartis (NOVN.VX) and GlaxoSmithKline ... Read Full Story